Analysis of information sources in references of the Wikipedia article "Cell-based vaccine" in English language version.
The virus in Ixiaro is grown in mammal cells ('Vero cells') under laboratory conditions.
Flucelvax was approved for active immunization against influenza for use in adults 18 years of age and older on 20 November 2012.
The main differences in manufacturing between Flucelvax and Optaflu are limited to minor differences in release specifications and the methods used to calculate HA concentration.
The main differences in manufacturing between Flucelvax and Optaflu are limited to minor differences in release specifications and the methods used to calculate HA concentration.